About Enterprise Therapeutics
Enterprise Therapeutics is a company based in Brighton (United Kingdom) founded in 2014 by Martin Gosling was acquired by Roche in October 2020. Enterprise Therapeutics has raised $86.19 million across 7 funding rounds from investors including Roche, Cystic Fibrosis Foundation and IP Group. The company has 9 employees. Enterprise Therapeutics offers products and services including ETD001. Enterprise Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Ikaria and Pulmatrix, among others.
- Headquarter Brighton, United Kingdom
- Employees 9
- Founders Martin Gosling
- SectorsHealthcare
- Website enterprisetherapeutics.com
- Social LinkedIn X
- Acquired by Roche (Oct 2020)
- Legal Name Enterprise Therapeutics Ltd
- Date of Incorporation 02 May, 2014
- Jurisdiction BRIGHTON, ENGLAND
Products & Services of Enterprise Therapeutics
Enterprise Therapeutics offers a comprehensive portfolio of products and services, including ETD001.
Inhaled blocker targeting cystic fibrosis symptoms to improve breathing.
Funding Insights of Enterprise Therapeutics
Enterprise Therapeutics has successfully raised a total of $86.19M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $33.02 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $86.19M
- Total Rounds 7
- Last Round Series B — $33.02M
- First Round $2.4M
(Feb 2015)
- Investors Count 9
All 7 funding rounds of Enterprise Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $33.02M | Series B | – | Panakes Partners | |
| Oct 2019 | $7.17M | Grant | – | – | |
| Apr 2018 | $41.14M | Series B | – | Versant Ventures, Novartis Venture Fund | |
| Apr 2017 | – | Grant | – | – | |
| Nov 2016 | $6.03M | Series B | – | – | |
| May 2015 | $3.6M | Series A | – | – | |
| Feb 2015 | $2.4M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Enterprise Therapeutics
Enterprise Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Cystic Fibrosis Foundation and IP Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | panakes.it | - | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Venture capital and advisory services are offered across multiple sectors. | 2001 | ipgroupplc.com | London, United Kingdom | |
- | – | epidarex.com | - | |
Investments in startups are focused on Europe and the US. | 1986 | imperialinnovations.co.uk | London, United Kingdom | |
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States | |
- | – | cysticfibrosis.org.uk | - | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Enterprise Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enterprise Therapeutics
17 people are tracked at Enterprise Therapeutics (7 in leadership, 10 in board & advisors); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Martin Gosling | Co-Founder | Leadership |
John Ford | CEO | Leadership |
Phil Boyd | CFO | Leadership |
Stephen Collingwood | Head of Chemistry | Leadership |
Henry Danahay | Head of Biology | Leadership |
Annabella Amatulli | Head Of Regulatory Affairs | Leadership |
Joanne Wagstaff | Head Of Finance | Leadership |
Jane Davies | Advisor | Board & advisors |
Luis Galietta | Advisor | Board & advisors |
Bart Dzikowski | Director | Board & advisors |
Craig Richardson | Director | Board & advisors |
Alex Mayweg | Director | Board & advisors |
Wisia Wedzicha | Advisor | Board & advisors |
Simon Ward | Advisor | Board & advisors |
Geert-Jan Mulder | Director | Board & advisors |
Peter Finan | Director | Board & advisors |
Richard C Boucher | Advisor | Board & advisors |
Complete people profiles for Enterprise Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enterprise Therapeutics
4 dated milestones of Enterprise Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Enterprise Therapeutics is founded.
- Funding First funding round of $2.4M.
- Exit Acquired by Roche.
- Funding Latest funding round, Series B, of $33.0M.
Competitors of Enterprise Therapeutics
Enterprise Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Ikaria and Pulmatrix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | – | Precision medicines for lung-related diseases are developed. | |
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | – | Developer of therapeutics for the treatment of inflammatory and rare diseases | |
| ikaria.com | 2005 | Hampton, United States | $434.92M | 429 | Therapies for respiratory-related cardiopulmonary disorders are developed. | |
| pulmatrix.com | 2003 | Lexington, United States | $67.11M | 28 | Developer of therapeutics for the treatment of respiratory diseases | |
| veronapharma.com | 2005 | London, United Kingdom | $56.02M | 27 | Respiratory disease drugs for asthma and COPD are developed. | |
| intermune.com | 1998 | Brisbane, United States | – | 359 | Therapies in pulmonology and orphan fibrotic diseases. |
Detailed competitors of Enterprise Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enterprise Therapeutics
Complete news archive for Enterprise Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Enterprise Therapeutics
10 companies that operate in the same segment as Enterprise Therapeutics (Pulmonology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Cancer detection diagnostics assays are developed and offered. | 2005 | Boulder, Colorado, United States | USD 200.16 M | USD 88.5 M | 273 | |
Therapeutic devices for nasal breathing improvement are developed. | 2011 | Sunnyvale, California, United States | USD 176.4 M | – | 66 | |
Non-invasive breath-based diagnostics for cancer and infectious diseases are developed. | 2004 | Cambridge, Cambridgeshire, United Kingdom | USD 166.55 M | – | 202 | |
Protein biologics are developed for treating rare diseases. | 2005 | San Diego, California, United States | USD 171.52 M | USD 190 K | 59 | |
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | 2008 | Austin, Texas, United States | USD 67.82 M | – | 59 | |
Developer of smart devices for treating pulmonary diseases | 1998 | Redwood City, California, United States | USD 280.91 M | USD 90.5 M | 291 | |
A norovirus vaccine is developed for infection prevention. | 2021 | Boston, Massachusetts, United States | USD 135 M | – | 14 | |
Oral small molecule drugs for chronic diseases are developed. | 2017 | San Francisco, California, United States | USD 233 M | – | 163 | |
Precision medicines for lung-related diseases are developed. | 2015 | Menlo Park, California, United States | USD 371 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Enterprise Therapeutics
Enterprise Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Enterprise Therapeutics is headquartered in Brighton, United Kingdom. It is registered at Brighton, East Sussex, United Kingdom.
Enterprise Therapeutics is a funded company, having raised a total of $86.19M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2.4M, raised on Feb 2015.
Enterprise Therapeutics has 9 employees.
Annual revenue of Enterprise Therapeutics is $1.69M as on Dec 31, 2021.
Enterprise Therapeutics was founded in 2014 and is based in Brighton, United Kingdom. Focus is placed on developing therapeutic solutions for respiratory diseases, including cystic fibrosis. Additional efforts are directed toward treatments for chronic obstructive pulmonary disease and severe asthma. Operations center on pharmaceutical research and development within the biotechnology sector, with activities conducted primarily in the UK.
Enterprise Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Enterprise Therapeutics offers ETD001.
Enterprise Therapeutics has 10 investors. Key investors include Roche, Cystic Fibrosis Foundation, IP Group, Imperial Innovations, and Panakes Partners.
Enterprise Therapeutics operates through Enterprise Therapeutics Ltd.
Yes. Enterprise Therapeutics was acquired by Roche in October 2020.